Open AccessComparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis
Author(s) -
Michael G. Whitfield,
David M. Engelthaler,
Christopher John Allender,
Megan Folkerts,
Tim H. Heupink,
Jason Limberis,
Robin M. Warren,
Annelies Van Rie,
John Metcalfe
Publication year - 2022
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.01907-21
Subject(s) - pyrazinamide , mycobacterium tuberculosis , sanger sequencing , tuberculosis , medicine , genotype , drug resistance , confidence interval , biology , microbiology and biotechnology , genetics , mutation , gene , pathology
Pyrazinamide is an important component of both drug-susceptible and drug-resistant tuberculosis treatment regimens. Although approximately 50% of rifampin-resistant isolates are also resistant to pyrazinamide, pyrazinamide susceptibility testing is not routinely performed due to the challenging nature of the assay.